Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OT 15

Drug Profile

OT 15

Alternative Names: EE-TP; Erythrocyte Encapsulated Thymidine Phosphorylase; OT-15

Latest Information Update: 25 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orphan Technologies
  • Developer Orphan Technologies; St. Georges University of London; Travere Therapeutics
  • Class Enzymes
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Metabolic disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mitochondrial myopathies

Most Recent Events

  • 20 Oct 2023 EryDel has been acquired and merged into Quince Therapeutics
  • 31 Jul 2023 St George's University of London in collaboration with Neovii Biotech withdrew the phase II TEETPIM trial in Mitochondrial myopathies (In adolescents, In adults, In the elderly) in United Kingdom (IV) due to change of circumstances with commercial partner (EudraCT2018-003000-39) (NCT03866954)
  • 25 Jul 2022 OT 15 is still in phase II trials for Mitochondrial myopathies (In adolescents, In adults, In the elderly) in United Kingdom (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top